First patient enrolled in platelet lysate biologic trial for dry eye with graft-versus-host disease

Cambium Medical Technologies has enrolled the first patient in a phase 1/2 study of its treatment for dry eye secondary to graft-versus-host disease, the company announced in a press release.
The randomized, multicenter, double-masked, placebo-controlled parallel study will enroll 60 patients at five U.S. sites to evaluate the safety and efficacy of Elate Ocular, a topical fibrinogen-depleted human platelet lysate biologic.
“To our knowledge, our study is the first to evaluate a standardized, cGMP processed, allogeneic vs. autologous, enriched platelet-rich-plasma lysate serum drop in a

Full Story →